Skip to main content

Advertisement

SpringerLink
Log in

Effect of rituximab on primary central nervous system lymphoma: a meta-analysis

  • Review Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

The effect of rituximab on primary central nervous system lymphoma (PCNSL) is controversial. We performed this meta-analysis to assess the efficacy of treatment with or without rituximab for PCNSL. We first conducted a search for qualified studies using PubMed, the Cochrane Library, and the Web of Science. The meta-analysis was conducted to compare odds ratios (ORs) with the corresponding 95% confidence interval (95% CI) for complete remission (CR) rate, progression-free survival (PFS), and overall survival (OS) using Review Manager 5.0. We included two randomized clinical trials and six retrospective studies in this meta-analysis. The results of our statistical analysis show that the use of rituximab was closely correlated with a higher CR (OR 1.70, 95% CI 1.17–2.46, P = 0.005), 2-year PFS (OR 2.11, 95% CI 1.08–4.11, P = 0.03), 5-year PFS (OR 2.54, 95% CI 1.64–3.93, P < 0.0001), 2-year OS (OR 2.40, 95% CI 1.73–3.34, P < 0.00001), and 5-year OS (OR 2.87, 95% CI 2.02–4.08, P < 0.00001). These results may help to inform therapeutic strategies including the use of rituximab and to improve therapeutic planning for PCNSL patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Batchelor T, Loeffler JS. Primary CNS lymphoma. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24:1281–8.

    Article  CAS  Google Scholar 

  2. Villano JL, Koshy M, Shaikh H, Dolecek TA, McCarthy BJ. Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer. 2011;105:1414–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS Statistical Report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. NEURO-ONCOLOGY. 2012;145:v1–49.

    Article  Google Scholar 

  4. Camilleribroët S, Crinière E, Broët P, Delwail V, Mokhtari K, Moreau A, et al. A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood. 2006;107:190–6.

    Article  Google Scholar 

  5. Braaten KM, Betensky RA, De LL, Okada Y, Hochberg FH, Louis DN, et al. BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2003;9:1063.

    CAS  Google Scholar 

  6. Rubenstein JL, Combs D, Rosenberg J, Levy A, McDermott M, Damon L, et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood. 2003;101:466–8.

    Article  CAS  PubMed  Google Scholar 

  7. Ewing JR, Brown SL, Lu M, Panda S, Ding GL, Knight RA, et al. Model selection in magnetic resonance imaging measurements of vascular permeability: gadomer in a 9L model of rat cerebral tumor. J Cerebr Blood F Metabol. 2006;26:310–20.

    Article  Google Scholar 

  8. Muldoon LL, Soussain C, Jahnke K, Johanson C, Siegal T, Smith QR, et al. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol. 2007;25:2295–305.

    Article  CAS  PubMed  Google Scholar 

  9. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1–12.

    Article  CAS  PubMed  Google Scholar 

  10. Parent N, Hanley JA. Assessing quality of reports on randomized clinical trials in nursing journals. Can J Cardiovasc Nurs. 2009;19:25–39.

    PubMed  Google Scholar 

  11. Wells GA, Shea BJ, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of non-randomized studies in meta-analysis. Appl Eng Agric. 2014;18:727–34.

    Google Scholar 

  12. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815.

    Article  CAS  PubMed  Google Scholar 

  13. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016;3:e217–27.

    Article  PubMed  Google Scholar 

  15. Luo W, Ji LH, Geng H, Ma XJ, Xiong H, Yin QC, et al. Clinical therapeutic efficacy of rituximab combined with methotrexate on primary central nervous system lymphoma]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016;24:444–7.

    PubMed  Google Scholar 

  16. Birnbaum T, Stadler EA, von Baumgarten L, Straube A. Rituximab significantly improves complete response rate in patients with primary CNS lymphoma. J Neurooncol. 2012;109:285–91.

    Article  CAS  PubMed  Google Scholar 

  17. Holdhoff M, Ambady P, Abdelaziz A, Sarai G, Bonekamp D, Blakeley J, et al. High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma. Neurology. 2014;83:235–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Kansara R, Shenkier TN, Connors JM, Sehn LH, Savage KJ, Gerrie AS, et al. Rituximab with high-dose methotrexate in primary central nervous system lymphoma. Am J Hematol. 2015;90:1149–54.

    Article  CAS  PubMed  Google Scholar 

  19. Mocikova H, Pytlik R, Sykorova A, Janikova A, Prochazka V, Vokurka S, et al. Role of rituximab in treatment of patients with primary central nervous system lymphoma: a retrospective analysis of the Czech lymphoma study group registry. Leukemia Lymphoma. 2016;57:2777–83.

    Article  CAS  PubMed  Google Scholar 

  20. Madle M, Krämer I, Lehners N, Schwarzbich M, Wuchter P, Herfarth K, et al. The influence of rituximab, high-dose therapy followed by autologous stem cell transplantation, and age in patients with primary CNS lymphoma. Ann Hematol. 2015;94:1853–7.

    Article  CAS  PubMed  Google Scholar 

  21. Gregory G, Arumugaswamy A, Leung T, Chan KL, Abikhair M, Tam C, et al. Rituximab is associated with improved survival for aggressive B cell CNS lymphoma. Neuro Oncol. 2013;15:1068–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Ferreri AJ, Reni M, Foppoli M, Martelli M, Pangalis GA, Frezzato M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet. 2009;374:1512–20.

    Article  CAS  PubMed  Google Scholar 

  23. Jezersek NB. Treatment outcomes and survival in patients with primary central nervous system lymphomas treated between 1995 and 2010—a single centre report. Radiol Oncol. 2012;46:346–53.

    Google Scholar 

  24. Cang S, Mukhi N, Wang K, Liu D. Novel CD20 monoclonal antibodies for lymphoma therapy. J Hematol Oncol. 2012;5:64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Perez-Callejo D, Gonzalez-Rincon J, Sanchez A, Provencio M, Sanchez-Beato M. Action and resistance of monoclonal CD20 antibodies therapy in B-cell Non-Hodgkin Lymphomas. Cancer Treat Rev. 2015;41:680–9.

    Article  CAS  PubMed  Google Scholar 

  26. Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol. 2002;29:2–9.

    Article  CAS  Google Scholar 

  27. Batchelor TT, Grossman SA, Mikkelsen T, Ye X, Desideri S, Lesser GJ. Rituximab monotherapy for patients with recurrent primary CNS lymphoma. Neurology. 2011;76:929–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Kimby E. Tolerability and safety of rituximab (MabThera (R)). Cancer Treat Rev. 2005;31:456–73.

    Article  CAS  PubMed  Google Scholar 

  29. Plate A, Havla J, Kümpfel T. Late-onset neutropenia during long-term rituximab therapy in neuromyelitis optica. Mult Scler Relat Disord. 2014;3:269–72.

    Article  PubMed  Google Scholar 

  30. Aksoy S, Harputluoglu H, Kilickap S, Dede DS, Dizdar O, Altundag K, et al. Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma. 2007;48:1307–12.

    Article  CAS  PubMed  Google Scholar 

  31. Tuccori M, Focosi D, Blandizzi C, Pelosini M, Montagnani S, Maggi F, et al. Inclusion of rituximab in treatment protocols for non-Hodgkin’s lymphomas and risk for progressive multifocal leukoencephalopathy. Oncologist. 2010;15:1214–9.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Akaishi T. Nakashima I [Rituximab (anti-CD20) in neurological disorders]. Brain Nerve. 2014;66:1167–78.

    PubMed  Google Scholar 

  33. Gea-Banacloche JC. Rituximab-associated infections. Semin Hematol. 2010;47:187–98.

    Article  CAS  PubMed  Google Scholar 

  34. Engsig FN, Hansen AB, Omland LH, Kronborg G, Gerstoft J, Laursen AL, et al. Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. J Infect Dis. 2009;199:77.

    Article  PubMed  Google Scholar 

  35. Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009;113:4834–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Rubenstein JL, Li J, Chen L, Advani R, Drappatz J, Gerstner E, et al. Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma. Blood. 2013;121:745–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Pels H, Schulz H, Manzke O, Hom E, Thall A, Engert A. Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximab. J Neurooncol. 2002;59:213–6.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by the National Natural Science Foundation of China (Grant Number 81172118).

Author information

Authors and Affiliations

  1. Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe Street (East), Erqi District, Zhengzhou, 450000, Henan, China

    Yue Song, Weili Xue, Yanjie Zhang & Mingzhi Zhang

  2. Institute of Clinical Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450000, Henan, China

    Yue Song, Yibo Wen, Weili Xue & Yanjie Zhang

  3. Lymphoma Diagnosis and Treatment Centre of Henan Province, Zhengzhou, 450000, Henan, China

    Mingzhi Zhang

  4. Department of Urodynamics Centre, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450000, Henan, China

    Yibo Wen

Authors
  1. Yue Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yibo Wen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Weili Xue
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yanjie Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mingzhi Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mingzhi Zhang.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Song, Y., Wen, Y., Xue, W. et al. Effect of rituximab on primary central nervous system lymphoma: a meta-analysis. Int J Hematol 106, 612–621 (2017). https://doi.org/10.1007/s12185-017-2316-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-017-2316-z

Keywords

Search

Navigation